A detailed history of Black Rock Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,427,250 shares of MDGL stock, worth $455 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,427,250
Previous 1,210,391 17.92%
Holding current value
$455 Million
Previous $323 Million 23.71%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$193.33 - $291.99 $41.9 Million - $63.3 Million
216,859 Added 17.92%
1,427,250 $400 Million
Q1 2024

May 10, 2024

SELL
$171.37 - $283.23 $372,044 - $614,892
-2,171 Reduced 0.18%
1,210,391 $323 Million
Q4 2023

Feb 13, 2024

BUY
$120.4 - $237.13 $21.7 Million - $42.6 Million
179,836 Added 17.41%
1,212,562 $281 Million
Q3 2023

Nov 13, 2023

SELL
$146.04 - $225.78 $1.58 Million - $2.44 Million
-10,811 Reduced 1.04%
1,032,726 $151 Million
Q2 2023

Aug 11, 2023

BUY
$203.88 - $312.0 $18.6 Million - $28.4 Million
91,027 Added 9.56%
1,043,537 $241 Million
Q1 2023

May 12, 2023

SELL
$231.06 - $307.08 $7.87 Million - $10.5 Million
-34,062 Reduced 3.45%
952,510 $231 Million
Q4 2022

Feb 13, 2023

SELL
$58.39 - $296.54 $755,099 - $3.83 Million
-12,932 Reduced 1.29%
986,572 $286 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $64,083 - $84,121
1,058 Added 0.11%
999,504 $65 Million
Q2 2022

Aug 12, 2022

BUY
$58.04 - $100.2 $2.43 Million - $4.2 Million
41,917 Added 4.38%
998,446 $71.5 Million
Q1 2022

May 12, 2022

BUY
$55.89 - $101.89 $391,341 - $713,433
7,002 Added 0.74%
956,529 $93.9 Million
Q4 2021

Feb 10, 2022

BUY
$72.34 - $95.09 $2.44 Million - $3.21 Million
33,738 Added 3.68%
949,527 $80.5 Million
Q3 2021

Nov 09, 2021

BUY
$78.35 - $105.02 $467,906 - $627,179
5,972 Added 0.66%
915,789 $73.1 Million
Q2 2021

Aug 11, 2021

BUY
$97.2 - $137.59 $88.4 Million - $125 Million
909,817 New
909,817 $88.6 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.45B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.